BiVictriX Therapeutics PLC BiVictriX and Abzena Enter Collaboration (7391S)
November 18 2021 - 1:00AM
UK Regulatory
TIDMBVX
RNS Number : 7391S
BiVictriX Therapeutics PLC
18 November 2021
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED
UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014
WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL)
ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A
REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO
BE IN THE PUBLIC DOMAIN.
BIVICTRIX THERAPEUTICS PLC
("BiVictriX" or the "Company")
BiVictriX and Abzena Collaborate to Manufacture Antibody-Drug
Conjugates
- BiVictriX has chosen Abzena for cost-effective and timely
manufacturing of its antibody-drug conjugates -
Alderley Park and Cambridge, UK - 18 November 2021 BiVictriX
Therapeutics plc (AIM: BVX), an emerging biotechnology company
applying a novel approach to develop next generation cancer
therapies using insights derived from frontline clinical experience
is pleased to announce a collaboration to manufacture BiVictriX's
antibody-drug conjugates ("ADC") with Abzena Limited ("Abzena"), a
partner research organisation for integrated discovery to cGMP
manufacturing solutions for biologics.
The collaboration will allow BiVictriX to cost-effectively
manufacture its anti-cancer ADCs for use in pre-clinical models
without the need for extensive manufacturing facilities of its own.
ADC production will be carried out in two cycles: the first cycle
being ADC manufacturing for proof-of-concept studies; and the
second cycle will cover ADC lead selection and optimisation. This
collaboration has been secured just three months after BiVictriX
listed on the AIM market of the London Stock Exchange, raising
gross proceeds of GBP7.5 million.
Tiffany Thorn, Chief Executive of BiVictriX Therapeutics plc,
commented: "Abzena is world-renowned for possessing the expertise
and capabilities to develop and manufacture antibody-drug
conjugates to the highest standards. Utilising Abzena's extensive
knowledge in the field will be highly valuable as we look to
expedite the development of our lead candidate, BVX001, and
additional pipeline candidates towards achieving key pre-clinical
milestones. We look forward to this initial collaboration marking
the beginning of a successful and ongoing partnership with
Abzena."
Campbell Bunce, Chief Scientific Officer of Abzena, said: "We're
delighted to be able to support the development of BiVictriX's ADCs
through our expert development, characterisation and manufacturing
services. BiVictriX's "twin antigen" targeting Bi-Cygni(R)
therapeutics present an innovative approach to target cancer cells
and we hope to support their development as best we can."
**Ends**
For more information, please contact:
BiVictriX Contacts:
BiVictriX Therapeutics plc
Tiffany Thorn, Chief Executive Officer Email: info@bivictrix.com
Iain Ross, Chairman
SP Angel Corporate Finance LLP (NOMAD
and Broker) Tel: +44 (0) 20 3470
0470
David Hignell, Caroline Rowe (Corporate
Finance)
Vadim Alexandre, Rob Rees (Sales and
Broking)
Panmure Gordon (UK) Limited (Joint Broker) Tel: +44 (0) 20 7886 2500
Rupert Dearden/Freddy Crossley/Emma Earl
Consilium Strategic Communications
Ashley Tapp, Suki Virji Tel: +44 (0) 20 3709 5700
Email: Bivictrix@consilium-comms.com
Abzena Contact:
Ramarketing
Kristy Harmer Tel: +44 (0)191 222 1242
Email:
kristy.harmer@ramarketingpr.com
About BiVictriX Therapeutics plc
BiVictriX is a UK-based drug discovery and development company
which is focused on leveraging clinical experience to develop a
class of highly selective, next generation cancer therapeutics
which exhibit superior potency, whilst eliminating
treatment-related toxicities.
The Company utilises a first-in-class approach to generate a
proprietary pipeline of Bi-Cygni(R) therapeutics which are designed
to selectively target antigen co-expression fingerprints, or "twin
antigens", on tumour cells, which are largely absent from healthy
cells. Whereas this concept has been validated in a clinical
diagnostic setting to support the diagnosis and monitoring of
haematological cancers, it has not yet been widely used in a
therapeutic setting.
BiVictriX has identified a diverse panel of novel
cancer-specific "twin antigens", across a broad range of cancer
indications including Diffuse Large B Cell Lymphoma, Acute Myeloid
Leukaemia and Blastic Plasmacytoid Dendritic Cell Neoplasm. The
Company is using these novel "twin-antigens" to develop more
effective and safer therapeutics to target cancers that are
expected to constitute orphan indications and currently constitute
areas of high unmet medical need.
Find out more about BiVictriX online at www.bivictrix.com
About Abzena
Abzena is a leading contract provider of integrated discovery,
development and manufacturing services for biologics and
bioconjugates. Abzena provides the most complete set of solutions
in integrated early discovery to mid-phase biotherapeutic and
bioconjugation drug development and manufacturing in the
biopharmaceutical industry. The company maintains resources around
the world, with facilities in the US and UK.
Abzena investors include Welsh, Carson, Anderson & Stowe,
one of the world's leading private equity investors, and Biospring
Partners (https://www.biospring.com/). For more information, please
see www.abzena.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCBRBRTMTBBBLB
(END) Dow Jones Newswires
November 18, 2021 02:00 ET (07:00 GMT)
Bivictrix Therapeutics (LSE:BVX)
Historical Stock Chart
From Apr 2024 to May 2024
Bivictrix Therapeutics (LSE:BVX)
Historical Stock Chart
From May 2023 to May 2024